Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo in Treated Primary or Early Stage HIV Infection on Viral Control Off ART

NCT04319367 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT04319367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04319367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo in Treated Primary or Early Stage HIV Infection on Viral Control Off ART
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Recruiting
Start date
May 17, 2021
Completion date
July 31, 2027
Enrollment
72 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids and infections